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Abstract
Background: Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders and it
causes long-lasting visceral pain and discomfort. AMPA receptor mediated long-term potentiation (LTP) has been
shown to play a critical role in animal models of neuropathic and inflammatory pain. No report is available for
central changes in the ACC of mice with chronic visceral pain.
Results: In this study, we used integrative methods to investigate potential central plastic changes in the anterior
cingulate cortex (ACC) of a visceral pain mouse model induced by intracolonic injection of zymosan. We found that
visceral pain induced an increased expression of AMPA receptors (at the post synapses) in the ACC via an
enhanced trafficking of the AMPA receptors to the membrane. Both GluA1 and GluA2/3 subunits were significantly
increased. Supporting biochemical changes, excitatory synaptic transmission in the ACC were also significantly
enhanced. Microinjection of AMPA receptor inhibitor IEM1460 into the ACC inhibited visceral and spontaneous
pain behaviors. Furthermore, we found that the phosphorylation of GluA1 at the Ser845 site was increased,
suggesting that GluA1 phosphorylation may contribute to AMPA receptor trafficking. Using genetically knockout
mice lacking calcium-calmodulin stimulated adenylyl cyclase subtype 1 (AC1), we found that AMPA receptor
phosphorylation and its membrane trafficking induced by zymosan injection were completely blocked.
Conclusions: Our results provide direct evidence for cortical AMPA receptors to contribute to zymosan-induced
visceral and spontaneous pain and inhibition of AC1 activity may help to reduce chronic visceral pain.
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Background
Irritable bowel syndrome (IBS) is a common functional
gastrointestinal disorder, characterized by colorectal
hypersensitivity, abdominal discomfort, bowel dysfunc-
tion, and chronic visceral pain [1, 2]. The refractory vis-
ceral pain is difficult to treat as the etiology and
pathological mechanisms of IBS are not fully under-
stood. Majority of previous studies mainly focused on
peripheral modulation and treatment for colorectal
hypersensitivity [3, 4]. Recent studies show that
enhanced primary sensory afferent is the culprit for pain
and colorectal hypersensitivity [2, 5]. In addition, human
brain imaging studies revealed that the long-term struc-
tural changes in the brain of IBS patients, suggesting the
role of central brain areas in IBS related chronic visceral
pain [6–9]. Considering the highly plastic nature of cor-
tical synapses, it is expected that enhanced peripheral
activity from inflammatory visceral organ could trigger
long-term plastic changes in the brain. Potential brain
areas involved are the insula cortex and anterior cingu-
late cortex (ACC) [10, 11]. Our recent studies found that
activity-dependent transcription of the Fos gene occurs
in the prefrontal cortex, ACC and the insular cortex of
the chronic visceral pain animal models [12].
It is well documented that peripheral noxious stimuli
trigger a series of neuronal activity along the afferent-
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ascending somatosensory pathways to central nervous
system (CNS). Cumulative evidence supports the notion
that forebrain neurons including those in the ACC and
insular cortex play a crucial role for pain-related percep-
tion [13, 14]. Based on evidence from recent studies,
long-term potentiation (LTP) of glutamatergic neurons
in the ACC is a key cellular mechanism for pathological
chronic pain [14–16]. Postsynaptic recruitment or mo-
dification of GluA1-containing α-amino-3-hydroxy-
5-methyl-4- isoxazolepropionic acid receptor (AMPA)
receptor is observed in the ACC of mice with peripheral
nerve injury. Adenylate cyclases (ACs) are enzymes for
the regulation and maintenance of different cell func-
tion. AC1 is primarily expressed in neurons, and is
activated in a calcium-calmodulin (CaM)-dependent
manner [17, 18]. AC1 acts as a downstream of glutamate
receptors and contributes to chronic pain-related neur-
onal plasticity in the cortex and spinal cord [19–21].
In the present study, we used integrative methods in-
cluding biochemical, electrophysiological, pharmaco-
logical, and behavioral techniques to explore the role of
AMPA receptor in the ACC of mice with intracolonic
injection of zymosan. Zymosan treatment causes obvious
visceral and spontaneous pain behaviors in mice. Pre-
synaptic neurotransmitter release, postsynaptic respon-
siveness, and the expressions of GluA1- and GluA2/
3-containing AMPA receptor were markedly increased
in the ACC of mice injected with zymosan. Pharmaco-
logical inhibition of AMPA receptor significantly re-
duced chronic visceral and spontaneous pain-related
behaviors in mice. Genetic deletion of AC1 abolished
the enhanced expressions of GluA1 and GluA2/3 in the
ACC of mice with chronic visceral pain.
Results
Zymosan-induced visceral and spontaneous pain
behaviors
Zymosan was used to induce experimental sterile in-
flammation [22, 23]. Behavioral tests were performed on
day 1, 7, and 14 after intracolonic injection with saline
or zymosan (Fig. 1a). Our recent study found that adult
mice with intracolonic injection of zymosan displayed
visceral and spontaneous pain behaviors [12]. Here, we
found that intracolonic injection of zymosan obviously
induced visceral pain behavior (29.3 ± 1.5 vs. 3.2 ± 0.5, F
(3,20) = 60.33, P < 0.01, one-way ANOVA, Dunnett T3
test, Fig. 1b), and reduced travel distance (9936.5 ± 326.9
vs. 14774.8 ± 535.6, F (3,20) = 10.44, P < 0.01, one-way
ANOVA, LSD test, Fig. 1c) and vertical counts (678.8 ±
61.6 vs. 971.2 ± 35.5, F (3,20) = 4.71, P < 0.05, one-way
ANOVA, LSD test, Fig. 1d) in mice on day 1 after the
injection. The pain-like behavior in mice treated with zy-
mosan persisted for two weeks (number of pain behav-
ior: 31.0 ± 2.0, P < 0.01 for 7d, 29.2 ± 2.3, P < 0.01 for
14d; travel distance: 10359.5 ± 802.8, P < 0.01 for 7d,
11557.6 ± 907.2, P < 0.01 for 14d; vertical counts: 586.5 ±
85.7, P < 0.01 for 7d, 715.7 ± 103.1, P < 0.05 for 14d;
Fig. 1b, c, and d). There was no significant difference
between day 1 and day 7 or day 14 groups in the num-
ber of pain behavior (P = 0.98 and P = 1.0), travel distance
(P = 0.67 and P = 0.22) and vertical counts (P = 0.40 and
P = 0.74), suggesting that zymosan induces long-lasting
changes in behaviors.
Expression of glutamatergic AMPA receptor in the ACC
AMPA receptors mediate most of the basal synaptic
transmission in the ACC and contribute to postsynaptic
Fig. 1 Intracolonic injection with zymosan induced visceral pain-like behaviors and enhanced expression of AMPA receptor in the ACC in mice. a The
time course for injected with zymosan and behavioral test. b-d Mice injected with zymosan exhibited obvious visceral pain behavior (b), and reduced
travel distance (c) and vertical counts (d) on day 1, 7, and 14 as compared with control. e Representative Western blot for GluA1 and GluA2/3 in the
ACC obtained from control and zymosan-injected mice. f-g The expressions of GluA1 (f) and GluA2/3 (g) were significantly enhanced on day 1, 7, and
14 in the ACC of mice injected with zymosan as compared to those of control mice. N = 6 mice per group. * P < 0.05, ** P < 0.01 vs. control
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plastic potentiation after peripheral nerve injury [24].
We next wanted to determine if there are alterations in
the AMPA receptor subtypes in the ACC of animals
with intracolonic injection of zymosan. First, we exam-
ined the total expression of GluA1 and GluA2/3 recep-
tors in the ACC, a brain region critical for perception of
physical and emotional discomfort [21, 25–27]. We
found that the total amount GluA1 and GluA2/3 recep-
tor subtypes were significantly increased in the ACC. On
day 1 after intracolonic injection of zymosan, the expres-
sions of GluA1 and GluA2/3 were significantly in-
creased, relative to control mice (GluA1: 158.0 ± 13.0 %,
F(3,20) = 6.21, P < 0.05, GluA2/3: 171.5 ± 13.3 %, F(3,20) =
8.15, P < 0.05, one-way ANOVA, Dunnett T3 test, Fig. 1e,
f and g). The increases in the expression levels of GluA1
and GluA2/3 receptors remained high on day 7 (GluA1:
172.8 ± 17.6 %, P < 0.05; GluA2/3: 186.0 ± 19.0 %, P < 0.05)
and day 14 (GluA1: 171.8 ± 16.9 %, P < 0.05; GluA2/3:
181.3 ± 16.0 %, P < 0.05). These findings indicate that co-
lonic inflammation induced by zymosan injection triggers
long-term increase in the expression of AMPA receptors
in the ACC.
Enhancement of AMPA receptor mediated synaptic
transmission in the ACC
To confirm that the upregulation of AMPA receptors
may contribute to synaptic transmission in the ACC, we
recorded AMPA receptor-mediated EPSCs in pyramidal
neurons of mice on day 7 after treated with zymosan
(Fig. 2a Top). Pyramidal neurons were identified by the
spike frequency adaptation in response to the prolonged
depolarizing-current injection. We found that AMPA re-
ceptor mediated EPSCs were significantly enhanced in
the ACC slices of mice injected with zymosan (Fig. 2a
Bottom). Synaptic input (stimulation intensity) – output
(EPSC amplitude) curves of AMPA receptor-mediated
currents were significantly shifted to the left in the ACC
slices of zymosan-treated mice compared to the control
mice (5 V: T = −3.24, P < 0.05; 6 V: T = −4.29, P < 0.01;
7 V: T = −5.68, P < 0.01; 8 V: F(1,50) = −2.68, P < 0.05; 9 V:
T = −2.89, P < 0.05; unpaired-T test, Fig. 2b). These re-
sults indicate that excitatory synaptic transmission is en-
hanced in the ACC of zymosan-treated mice.
Paired-pulse facilitation (PPF) is a form of short-term
synaptic plasticity. To determine if enhanced excitatory
synaptic transmission in the ACC is due to presynaptic
or postsynaptic mechanisms, we recorded PPF at differ-
ent stimulus intervals (35, 50, 75, 100, and 150 ms) in
the ACC of mice on day 7 after saline or zymosan injec-
tion (Fig. 2c). Comparing the recordings from the two
groups, PPF was significantly reduced in the ACC of
mice after intracolonic zymosan injection (35 ms: T =
4.20, P < 0.01; 50 ms: T = 3.44, P < 0.05; 75 ms: T = 3.24,
P < 0.05; 100 ms: T = 2.65, P < 0.05; 150 ms: T = 1.61,
P = 0.17; unpaired-T test, Fig. 2d). We also tested the
PPF in motor cortex of the same mice and we did not
conclude any differences between control and
zymosan-treated mice (35 ms: T = 0.11, P = 0.92;
50 ms: T = −0.03, P = 0.98; 75 ms: T = −0.26, P = 0.80;
100 ms: T = 0.22, P = 0.83; 150 ms: T = −0.14, P = 0.89;
unpaired-T test, Fig. 2e). These findings suggest that
an increase of presynaptic neurotransmitter release
may at least in part contribute to the enhanced excita-
tory synaptic transmission in the layer II-III of the
ACC in animal model of chronic visceral pain.
Enhanced mEPSCs in the ACC
Next, we tested the miniature excitatory postsynaptic
current (mEPSCs), which display the probability of pre-
synaptic neurotransmitter release and postsynaptic re-
sponsiveness. The ACC slices of mice on day 7 after
saline or zymosan injection were used in the presence of
0.5 μM tetrodotoxin. A robust augmentation of ampli-
tude was observed in the ACC slices from zymosan group
(Fig. 3a). Both frequency and amplitude of mEPSCs were
significantly increased in the ACC neurons of mice with
intracolonic injection of zymosan compared to the
control mice (Frequency: T = −3.05, P < 0.05; Ampli-
tude: T = −2.82, P < 0.05; unpaired-T test, Fig. 3b and c).
The results suggest that the increases of presynaptic
neurotransmitter release and postsynaptic responsive-
ness both likely contribute the enhanced excitatory syn-
aptic transmission in the ACC of mice with zymosan
administration.
Inhibition of AMPA receptor reduced visceral pain-
induced spontaneous pain behaviors
Our biochemical and electrophysiological results consist-
ently suggest that the increased expression of AMPA re-
ceptors may contribute to chronic visceral pain. To test
this, we performed behavioral experiments in freely
moving animals. IEM 1460, a voltage-dependent open-
channel blocker of AMPA receptor, blocks GluA2-
lacking (Ca2+-permeable) receptors (IC50 = 2.6 μM) more
potently than GluA2-containing receptors (IC50 =
1102 μM) [28]. IEM 1460 was microinjected into the
ACC bilaterally in mice on day 7 after saline or zymosan
injection (Fig. 4a and b), and then behavior tests were
started at 45 min after microinjected with IEM1460.
Consistent with our previous study, the mice with zymo-
san treatment exhibited visceral pain behavior (28.0 ± 1.6
vs. 3.3 ± 0.9, F(7, 40) = 78.40, P < 0.01; one-way ANOVA,
Dunnett T3 test, Fig. 4c), and the decreased travel dis-
tance (8758.0 ± 610.8 vs. 16175.5 ± 465.0, F(7, 40) = 61.89,
P < 0.01; one-way ANOVA, LSD test, Fig. 4d), vertical
counts (431.7 ± 73.9 vs. 1042.3 ± 76.9, F(7, 40) = 10.69,
P < 0.01, one-way ANOVA, LSD test, Fig. 4e), ambulatory
counts (1327.3 ± 123.4 vs. 2328.5 ± 147.1, F(7, 40) = 13.89,
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P < 0.01, one-way ANOVA, LSD test, Fig. 4f), stereotypic
counts (3244.3 ± 244.8 vs. 5011.3 ± 270.0, F(7, 40) = 12.31,
P < 0.01, one-way ANOVA, LSD test, Fig. 4g), and jump
counts (60.7 ± 10.5 vs. 120.8 ± 13.4, F(7, 40) = 7.06, P < 0.01,
one-way ANOVA, LSD test, Fig. 4h) in open field test.
Microinjection with IEM 1460 markedly inhibited the ef-
fects of zymosan on visceral pain behavior (16.3 ± 1.6 vs.
28.0 ± 1.6, P < 0.05, Fig. 4c), travel distance (15299.2 ±
556.0 vs. 8758.0 ± 610.8, P < 0.01, Fig. 4d), vertical counts
(848.2 ± 80.6 vs. 431.7 ± 73.9, P < 0.01, Fig. 4e), ambulatory
counts (2167.5 ± 150.3 vs. 1327.3 ± 123.4, P < 0.01, Fig. 4f),
stereotypic counts (4336.0 ± 326.2 vs. 3244.3 ± 244.8,
P < 0.01, Fig. 4g), and jump counts (93.0 ± 7.8 vs. 60.7 ±
10.5, P < 0.01, Fig. 4h). The inhibitory effect of IEM 1460
is relatively selective, and it had no effect on number of
pain behavior (P = 1.0, Fig. 4c), traveled distance (P = 0.82,
Fig. 2 Enhancement of synaptic transmission in the ACC of animal model of IBS. a The location of stimulation and recording (top), and
representative synaptic input–output curves in the ACC slices from control and zymosan-injected mice (bottom). b The amplitude of EPSCs was
obviously enhanced in the ACC slice of mice injected with zymosan (n = 11/6 mice) as compared with that of control mice (n = 10/6 mice). c The
location of the ACC and motor cortex in coronary slice. d Paired-pulse ratio (the ratio of EPSC2/EPSC1) was recorded at intervals of 35, 50, 75, 100,
and 150 ms from control (n = 9/6 mice) and zymosan-injected mice (n = 9/6 mice). PPF was markedly reduced in the ACC of mice injected with
zymosan at intervals of 35, 50, 75, and 100 ms. e PPF in motor cortex neurons had no difference in control (n = 9/6 mice) and zymosan-injected
mice (n = 11/6 mice). * P < 0.05, ** P < 0.01 vs. control
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Fig. 4d), vertical counts (P = 0.80, Fig. 4e), ambulatory
counts (P = 0.80, Fig. 4f), stereotypic counts (P = 0.90,
Fig. 4g), and jump counts (P = 0.58, Fig. 4h) in control
mice. These results provide direct evidence that enhanced
AMPA receptors contribute to visceral and spontaneous
pain-like behaviors in mice with zymosan intracolonic
injection.
Trafficking of AMPA receptors to plasma membrane
The results above showed the key role of AMPA recep-
tor in the ACC of mice with chronic visceral pain. Next,
we want to characterize the increased AMPA receptors
in the ACC of mice after zymosan injection. Previous
studies in the hippocampus and ACC show that traffick-
ing of AMPA receptors to the membrane play important
roles in synaptic potentiation [29–31]. In our previous
study of neuropathic pain, we found that AMPA recep-
tors shift their expression on membranes; and contribute
to enhanced sensory transmission in the ACC and insu-
lar cortex [20, 32]. To examine possible changes in the
distribution of AMPA receptors, we performed biochem-
ical analysis of membrane and cytoplasmic GluA1 and
GluA2/3. We selected day 7 and 14 after intracolonic zy-
mosan injection, since the upregulation of AMPA recep-
tors in the ACC reached its peak at these time points.
As shown in Fig. 6a, the membrane expression of GluA1
and GluA2/3 were significantly increased on day 7
(GluA1: 182.9 ± 6.4 %, F(2,15) = 45.25, P < 0.01; GluA2/3:
150.1 ± 3.0 %, F(2,15) = 32.71, P < 0.01, one-way ANOVA,
Dunnett T3 test, Fig. 5a, b, and c) as compared with
those of control group. On the day 14, the membrane
proteins of GluA1 and GluA2/3 sustained high level
(GluA1: 169.8 ± 9.5 %, P < 0.01; GluA2/3: 132.7 ± 7.1 %,
P < 0.05, Fig. 5a, b, and c), and there was no difference
between day 7 and 14 (GluA1: P = 0.60; GluA2/3: P = 0.15).
Interestingly, the cytoplasmic level of GluA1 and GluA2/3
did not change at both time frames (GluA1: F(2,15) = 0.08,
P = 1.00 and P = 0.94, one-way ANOVA, Dunnett T3 test;
GluA2/3: F(2,15) = 0.46, P = 0.71 and P = 0.58, one-way
ANOVA, LSD test, Fig. 5d, e, and f).
The phosphorylation of GluA1 at the Ser845 site
We next wanted to know which signaling pathway ac-
counts for the increased trafficking of AMPA receptors.
In this regard, protein kinase A (PKA) has been shown
to play roles in plasticity-related AMPA receptor traf-
ficking [33, 34]. In addition, our previous studies found
that AC1-cAMP-PKA activity is critical for the regula-
tion of AMPA receptor phosphorylation and function
[19, 32]. Therefore, the phosphorylation of GluA1 at the
Ser845 site was detected as phosphorylation of GluA1 at
the Ser845 site is a substrate of PKA. Compared with
that of control group, the phosphorylation of GluA1 at
the Ser845 site was increased on day 7 (179.4 ± 18.2 %,
P < 0.05) and 14 (185.8 ± 14.4 %, P < 0.01) after zymosan
injection (F(3,20) = 6.57, one-way ANOVA, Dunnett T3
test, Fig. 5g and h). We also examined phosphorylation
of GluA1 at the Ser845 site on day 1 after zymosan injec-
tion and we found no statistically significant difference
compared to control group (166.4 ± 20.2 %, P = 0.10). The
percentage increase in the phosphorylation was similar on
day 7 and 14, which were comparable with that in the
ACC of neuropathic pain animal model [32].
Calcium-stimulated Adenylyl cyclase 1 (AC1) involved in
the visceral pain-induced AMPA receptor changes
Our previous studies reported that AC1 is necessary to
induce an increase of AMPA receptor phosphorylation
and membrane expression after by nerve injury [32].
Therefore, we want to check if AC1 is required for these
changes induced by intracolonic zymosan injection. In-
deed, we found that the increased expression of GluA1
and GluA2 receptors were completely abolished or
partly reduced in AC1−/− mice (GluA1: 81.0 ± 8.7 % vs.
146.7 ± 4.9 %, F (3,20) = 24.15, P < 0.01; GluA2/3: 111.1 ±
11.7 % vs. 146.5 ± 4.6 %, F (3,20) = 7.47, P = 0.13; one-way
ANOVA, Dunnett T3 test, Fig. 6a, b, and c). The mem-
brane and cytoplasmic proteins of the ACC from AC1
WT and AC1−/− mice were isolated on day 7 after
Fig. 3 Enhanced mEPSCs in the ACC of animal model of IBS.
a Representative mEPSCs recorded in pyramidal neurons at a
holding potential of −70 mV from control and zymosan-injected
mice. b Cumulative inter-event interval (left) and amplitude (right)
histograms of mEPSCs recorded in slices of control (n = 10/6 mice)
and zymosan-injected mice (n = 11/6 mice). c Summary plots of
mEPSC data. The frequency (left) and amplitude (right) of mEPSCs
were significantly enhanced in the ACC slices of mice injected
with zymosan. * P < 0.05 vs. control
Liu et al. Molecular Brain  (2015) 8:76 Page 5 of 13
zymosan injection. We found that the increased traffick-
ing of GluA1 to the membrane was completely abolished
in the ACC of AC1−/− mice (107.1 ± 4.5 % vs. 159.3 ±
5.7 %, F(3, 20) = 39.09, P < 0.01; one-way ANOVA,
Dunnett T3 test, Fig. 6d and e). However, the increased
trafficking of GluA2/3 was partially reduced in the ACC
of AC1−/− mice (129.1 ± 7.6 % vs. 167.8 ± 7.9 %, F(3, 20) =
18.42, P < 0.05; one-way ANOVA, Dunnett T3 test,
Fig. 6d and f). Furthermore, we noticed that the cyto-
plasmic expression of GluA1 was reduced in AC1−/−
mice as compared with WT mice (52.3 ± 3.6 %, F(3, 20) =
82.95, P < 0.01, one-way ANOVA, Dunnett T3 test,
Fig. 6g and h). There was no difference on cytoplasmic
expression of GluA2/3 between AC1 WT and AC1−/−
mice (F(3, 20) = 0.87, P = 1.00; one-way ANOVA, Dunnett
T3 test, Fig. 6g and i).
We next examined the phosphorylation of GluA1 at
Ser845 site. The increased phosphorylation of GluA1 at
Ser845 site was completely abolished the ACC of AC1−/−
mice (81.3 ± 7.9 % vs. 156.0 ± 12.1 %, F(3, 20) = 21.25,
P < 0.01; one-way ANOVA, Dunnett T3 test, Fig. 6j and k).
This result suggests that the reduced phosphorylation
of GluA1 at the Ser845 site may be related to the de-
creased expression and trafficking of GluA1.
Discussion
In the present study, we investigated central postsynap-
tic changes in pain-related cortical area using a mouse
model of chronic visceral pain. We showed long-term
increases in AMPA receptors and excitatory synaptic
transmission in these animals. Using genetic knockout
mice, we found that calcium-stimulated AC1 plays an
important role in trafficking of GluA1 and GluA2/3 re-
ceptors. It may act through phosphorylated GluA1
Ser845. These findings clearly demonstrate that cortical
plastic changes of excitatory transmission in the ACC
may play important roles in chronic visceral pain and
discomfort. These observations also support our recent
study that showed the analgesic effects of a selective
AC1 inhibitor NB001 [12].
Fig. 4 The effect of AMPA inhibitor IEM1460 on behavioral test in the animal model of IBS. a The time course of cannulation surgery, zymosan
injection, microinjection, and behavioral tests. b Schematic showing cannula tip placements in the ACC. C-H) The mice injected with zymosan
exhibited obvious visceral pain behavior (c), the decreased travel distance (d), vertical counts (e), ambulatory counts (f), stereotypic counts (g),
and jump counts (h) in open field test. However, the microinjection with IEM 1460 totally blocked the effects of zymosan in mice. IEM 1460 had
no effect in control mice. N = 6 mice per group, ** P < 0.01 vs. control (No cannula), # P < 0.05, ## P < 0.01 vs. zymosan + IEM 1460
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ACC and chronic visceral pain
Cumulative evidence consistently suggests that neurons
of the ACC are involved in pain-related perception, es-
pecially in chronic pain [21, 35–38]. Most of these stud-
ies about the role of the ACC are limited in animal
models using the injuries to somatosensory inputs such
as inflammatory pain and neuropathic pain (Table 1);
there is less studies of possible synaptic changes in the
ACC in animal models using the injuries to visceral or-
gans. Several lines of evidence however indicate that
neurons in the ACC may play important roles in visceral
pain. In patients with IBS, human imaging data have
shown that activity in the brain regions of the ACC, in-
sula and amygdala is enhanced from afferent input by
visceral stimulus [39–42]. Similar activation of the ACC,
insular cortex, prefrontal cortex and thalamus have been
reported in the animal model with visceral pain [43]. In
addition, ACC and related supraspinal structures may
affect spinal visceral pain transmission. Electrical stimu-
lation of the ACC causes the enhancement of viscero-
motor response to colorectal distention and ACC lesions
reduce visceromotor response to colorectal distention in
rats [44]; indicating that similar cortical descending fa-
cilitatory modulation may exist for visceral pain [35, 45].
Finally, the GluN2B-containing NMDA receptors, post-
synaptic CaMKII, and extracellular signal-regulated
kinase-1 and −2 (ERK1/2) in the ACC mediate visceral
pain in animals [46–49]. In present study, we provided
direct evidence to show the role of AMPA in the ACC
in the development of visceral pain via Western blot
analysis, electrophysiological record, ACC local drug in-
fusion technique and behavioral tests.
AMPA receptor subtypes and synaptic plasticity in the ACC
AMPA receptors are the major excitatory neurotrans-
mitter receptors and mediate the majority of fast synap-
tic transmission in central nervous system. There are
four subunits of AMPA receptor: GluA1, GluA2, GluA3,
and GluA4 [50]. Out of the four subunits, GluA1 is the
most significant as it induces the trafficking and integra-
tion of AMPA receptors within the synaptic membranes
[51]. The vast majority of AMPA receptors in the adult
brain contain GluA2, which always render the channel
impermeable to calcium. The trafficking of GluA1 is en-
hanced in the absence of GluA2 [52]. In the hippocam-
pus, increased levels of GluA1 ameliorates memory in
mice [53] and synaptic AMPA receptor delivery is essen-
tial for learning and memory [54]. Our previous studies
have revealed that only GluA1 expression is increased
after somatic chronic inflammatory and neuropathic
pain and this increased expression of GluA1 may contrib-
ute to the related behavioral sensitization [32, 35, 51].
Interestingly, in this study, we found that the expressions
of GluA1 and GluA2/3 are both increased in the ACC of
animal model. IEM1460 significantly inhibited visceral
pain-like behaviors, which suggests that GluA1 is partially
involved in visceral pain in the ACC, we could not rule
out the role of GluA2/3 in the development of visceral
pain. These differences provide a distinct pattern of post-
synaptic changes for visceral related chronic pain.
Synaptic plasticity is a crucial mechanism for learning,
memory, and chronic pain [14, 15]. At the synaptic level,
potentiation of excitatory transmission caused by injury
may be mediated by the enhancement of glutamate release
from presynaptic terminals and potentiated postsynaptic
Fig. 5 Zymosan injection facilitated the trafficking of AMPA receptor
into membrane and phosphorylation of GluA1 at the Ser845 site in
the ACC. a Representative Western blot for GluA1 and GluA2/3 on
membrane protein in the ACC obtained from control and zymosan-
injected mice. b-c The expressions of GluA1 and GluA2/3 on membrane
in the ACC were significantly enhanced on day 7, and 14 after mice
injected with zymosan. d Representative Western blot for GluA1 and
GluA2/3 on cytosolic protein in the ACC obtained from control and
zymosan-injected mice. e-f) The expressions of GluA1 and GluA2/3
on cytosol in the ACC had no difference among three groups.
g Representative Western blot for phosphorylated GluA1 at the
Ser845 site in the ACC obtained from control and zymosan-
injected mice. h The phosphorylation of GluA1 at the Ser845 site
was significantly enhanced in the ACC on day 1, 7, and 14 after
mice injected with zymosan. N = 6 mice per group, * P < 0.05,
** P < 0.01 vs. control
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responses of AMPA receptors [15]. Our electrophysio-
logical data further confirm an enhanced excitatory synap-
tic transmission in the ACC of zymosan-treated mice,
which is attributed to the increases of presynaptic neu-
rotransmitter release and postsynaptic responsiveness.
Presynaptic and postsynaptic changes of excitatory trans-
mission are similar to previous researches about somatic
inflammatory and neuropathic pain [32, 37]. In addition
to the ACC, it is possible that other regions of the brain
are also involved in processing of visceral pain, such as the
frontal lobe, hippocampus and cornu dorsale [55, 56].
AC1-cAMP-PKA signaling pathway in the ACC
AC1 catalyzes the conversion of adenosine triphosphate
(ATP) to 3’,5’-cyclic AMP (cAMP). AC1-cAMP-PKA sig-
naling pathway is important for somatic inflammation and
neuropathic pain. Genetic deletion of AC1 or genetic
knock-in lacking phosphorylation of the Ser845 site blocks
the enhancement of the GluA1 subunit [20, 35, 57]. AC1
is selectively expressed in neurons and previous studies
show that it did not play important roles in learning and
memory [17]. The present findings extend the critical role
of AC1-cAMP-PKA signaling pathway in chronic visceral
Fig. 6 Genetic deletion of AC1 reduced the increased expression of AMPA receptor. a Representative Western blot for GluA1 and GluA2/3 in the
ACC obtained from WT or AC1−/− control and zymosan-injected mice. b-c The enhanced expressions of GluA1 (b) and GluA2/3 (c) were reduced
in the ACC of AC1−/− mice on day 7 after zymosan treatment. d Representative Western blot for membranous proteins of GluA1 and GluA2/3 in
the ACC obtained from WT or AC1−/− control and zymosan-injected mice. e-f The enhanced membranous expressions of GluA1 (e) and GluA2/3
(f) were completely or partly blocked in the ACC of AC1−/− mice on day 7 after zymosan treatment. g Representative Western blot for cytoplasmic
proteins of GluA1 and GluA2/3 in the ACC obtained from WT or AC1−/− control and zymosan-injected mice. h The cytoplasmic protein of GluA1
was significantly decreased in the ACC of AC1−/− mice as compared with that in WT mice. i There was no difference on cytoplasmic protein of
GluA2/3 among four groups. j Representative Western blot for phosphorylated GluA1 at the Ser845 site in the ACC obtained from WT or AC1−/−
control and zymosan-injected mice. k The increased phosphorylation of GluA1 at the Ser845 site was significantly inhibited in the ACC of AC1−/−
mice on day 7 after zymosan treatment. N = 6 mice per group, * P < 0.05, ** P < 0.01 vs. WT control; # P < 0.05, ## P < 0.01 vs. WT for 7d
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pain, and suggest that AC1 selective antagonist NB001
may be used to treat chronic visceral pain [12].
In Fig. 7, we provided a model for explaining the signal-
ing pathways for chronic visceral pain related plasticity in
the ACC. Visceral injuries trigger the release of glutamate
in the ACC and subsequent calcium influx into the post-
synaptic membrane mediates the activation of Ca2+/CaM
dependent AC1. Activation of AC1 catalyzes the conver-
sion of ATP to 3’,5’-cyclic AMP (cAMP) and activates
PKA. PKA phosphorylates the GluA1-containing AMPA
receptor at Ser845 site, which promotes AMPA receptor
trafficking to the membrane. In addition, AC1 also con-
tributes to the trafficking of GluA2 and 3 to the mem-
brane. Blocking either AMPA or AC1 could produce
powerful antinociceptive effect on spontaneous pain in-
duced by intracolonic injection with zymosan. These re-
sults provide novel cortical mechanisms to chronic
visceral pain and AC1 inhibitors may be useful for control
IBS-related chronic visceral pain in patients.
Conclusions
In this study, we demonstrate that genetic deletion of AC1
abolishes the upregulation of GluA1 caused by zymosan
injection. Together with previous studies of somatic
chronic pain models, it strongly indicates the important
roles of AMPA GluA1 receptor in cortical sensitization
that contribute to chronic somatic and visceral pain. Un-
like somatic chronic pain models, we also found that
GluA2/3 receptors were upregulated in chronic visceral
pain model. The activity of AC1 partially contributes to
this upregulation. Future studies are clearly needed to re-
veal exact molecular mechanism for the upregulation.
Methods
Animals
Adult male C57BL/6 mice (age 8–12 weeks) were pur-
chased from Charles River Laboratories (St. Constant,
Quebec, Canada) or Animal Center (Xi’an Jiaotong Uni-
versity). AC1 knock out mice (AC1−/−, age 8–9 weeks)
were bred from a C57BL/6 genetic background. The
mice were housed with water and food provided ad libi-
tum under standard laboratory conditions (12 h light/
12 h dark, temperature 22-26 °C, humidity 55-60 %). All
experiments were performed in accordance with proto-
cols approved by the Animal Care Committee of the
University of Toronto and Xi’an Jiaotong University.
Chronic visceral pain mouse model
To induce visceral pain, mice were treated with intracolo-
nic injection with zymosan (derived from Saccharomyces
Table 1 Studies performed on chronic pain in the ACC of mice
Chronic pain ACC References
Inflammatory pain Increased synaptic GluA1 subunits Bie et al., 2011
Activation of mu opioid receptor inhibits the excitatory glutamatergic transmission Zheng, 2010
GluA1 but not GluA2 contributes to LTP Toyoda et al., 2009
Increased transmitter release and number of available vesicles Toyoda et al., 2009
Enhanced presynaptic glutamate release and neuronal cAMP Wu et al., 2008
Enhanced presynaptic neurotransmitter release Zhao et al., 2006
Inflammatory pain & Neuropathic pain Long-term temporal imprecision of information coding Li et al., 2014
Activation of Erk Wei et al., 2008
Neuropathic pain Postsynaptic GluA1 accumulation Chen et al., 2014
Long-term enhancement of cortical-spinal projecting cells Chen et al., 2014
Disinhibition of the ACC Blom et al., 2014
Long-term changes in spontaneous membrane-potential oscillations Ning et al., 2013
LTD impairment Kang et al., 2012
Activation of PKMζ Li et al., 2010
Reduced cannabinoid receptor 1 activity Hoot et al., 2010
Increased transmitter release Toyoda et al., 2009
Presynaptic and postsynaptic amplifications Xu et al., 2008
Bone cancer pain LTD impairment Chiou et al., 2012
Visceral pain Facilitation of synaptic transmission Wang et al., 2013
Increased expression of Fos in the CNS Zhang et al., 2014
Long-term enhancement of AMPA receptors in the ACC This study
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cerevisiae, Sigma, St. Louis, MO), a Glucan prepared from
yeast cell wall characterized as a protein-carbohydrate
complex [12]. Briefly, the mice were anesthetized with 1-
3 % isoflurane inhalation. A volume of 0.1 ml zymosan
suspension (30 mg/ml in saline) was rectally administered
into the colons of mice by a 22-gauge, 24-mm-long plastic
feeding needle over a period of 2 minutes. Control mice
were rectally administered with 0.1 ml saline. Zymosan or
saline was given daily for 3 consecutive days.
Behavioral test
Visceral pain behavior
Visceral pain behavior test was performed according to
the method of Laird [58]. The numbers of licking abdo-
men at the absence of other grooming behavior, whole
body stretching, flattening the abdomen against the
floor, and arched posture for 1–2 sec were recorded in a
period of 10 min.
Open field test
Open field test was performed from 9:00 am to
12:00 pm in a blind manner on day 1, 7, and 14 after
intracolonic injection of zymosan. The mice were accli-
matized to the observation room for 30 min before be-
havioral test. Mice were placed in the center of a novel
open field (43.2 × 43.2 × 30.5 cm3, Med Associates, St.
Albans, Vermont) inside a dimly lit isolation chamber
(<50 lux) with a fan. The traval distance, vertical counts,
ambulatory counts, stereotypic counts, and jump counts
of animal were recorded for 30 min by an activity moni-
toring system with paired sets of photo beams (Activity
Monitor, Med Associates, St. Albans, Vermont).
Western blot analysis
The ACC of each group of mice were separately dis-
sected in cold ACSF and homogenized in lysis buffer
composed of 10 mM tris-Cl (pH 7.4), 150 mM NaCl,
1 mM EDTA, 0.1 % SDS, 1 % Triton X-100, 1 % sodium
deoxycholate. The lysis buffer contained a protease in-
hibitor cocktail and phosphatase inhibitor cocktails 2
and 3 (Sigma, St. Louis, MO). Membrane and cytoplas-
mic proteins were prepared according to instruction of
membrane protein extraction reagent kit (Pierce,
Thermo, Rockford, USA). The samples were purified
and concentrated according to the instruction provided by
SDS-Page Sample Prep Kit (Pierce, Thermo, Rockford,
USA). Equal amounts of protein (20 μg) from each sample
was separated on a 7.5 % SDS-PAGE gels and transferred
to polyvinylidene difluoride (PVDF) membrane to be
immunoblotted with anti-GluA1 (dilution ratio, 1:5000,
abcam), anti-GluA2/3 (dilution ratio, 1:1000, millipore),
anti- phosphorylation-GluA1-Ser845 (dilution ratio,
1:1000, millipore), and β-actin (dilution ratio, 1:50000,
Sigma) antibodies at 4 °C overnight. The membranes
were incubated with horseradish peroxidase-conjugated
secondary antibodies (anti-rabbit/anti-mouse IgG for
the primary antibodies) at room temperature for 1 h.
The band intensity was expressed relative to β-actin for
data quantification.
In vitro whole-cell patch-clamp recording
Coronal brain slices (300 μm) of the ACC were prepared
using standard methods [32, 57, 59]. Slices were trans-
ferred to submerged recovery chamber with oxygenated
(95 % O 2 and 5 % CO2) artificial cerebrospinal fluid
(aCSF) containing (in mM) 124 NaCl, 2.5 KCl, 2 CaCl2,
1MgSO4, 25 NaHCO3, 1 NaH2PO4, and 10 glucose at
room temperature for a minimum of 1 h. Whole-cell
patch clamp recordings were performed in a recording
chamber on the stage of a BX51W1 microscope
equipped with infrared differential interference contrast
optics for visualization. Excitatory postsynaptic currents
(EPSCs) were recorded from layer II/III neurons with an
Axon 200B amplifier (Molecular Devices), and the stim-
ulations were delivered by a bipolar tungsten stimulating
electrode placed in layer V/VI of the ACC. AMPA
Fig. 7 A model showing the molecular mechanism for the
upregulation of AMPA receptors in the ACC of IBS animal model.
Visceral injuries trigger the release of glutamate in the ACC via
ascending visceral pathways. Activation of NMDA receptors lead to
calcium fluxes into the postsynaptic membrane. These cause the
activation of Ca2+/CaM dependent AC1. Activation of AC1 catalyzes
the conversion of ATP to cAMP and activates PKA and downstream
signaling pathway, which in turn produces the phosphorylation of
the GluA1-containing AMPA receptor at Ser845 site, GluN2B and
PKMζ. The phosphorylation of the GluA1 at Ser845 site promotes
AMPA receptor trafficking to membrane. Increases in postsynaptic
AMPA receptors as well as the enhancement of glutamate release
significantly enhance excitatory synaptic transmission in the ACC,
and then lead to amplification of chronic visceral pain
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receptor-mediated EPSCs were induced by repetitive
stimulations at 0.05 Hz, and the neurons were voltage
clamped at −70 mV in the presence of a N-methyl-D-as-
partate (NMDA) antagonist AP5 (50 μM). The recording
pipettes (3–5 MΩ) were filled with intracellular solution,
containing (in mM) 145 K-gluconate, 5 NaCl, 1 MgCl2,
0.2 EGTA, 10 HEPES, 2 Mg-ATP, 0.1 Na3-GTP, and 10
phosphocreatine disodium (adjusted pH 7.2 with KOH).
For miniature EPSC (mEPSC) recording, 0.5 μM TTX was
applied to the perfusion solution. Picrotoxin (100 μM) was
present throughout the entire recording session for all of
the experiments to block GABAA receptor-mediated in-
hibitory synaptic currents. Access resistance was 15–30
MΩ and monitored throughout the experiment and
data were discarded if access resistance deviated >15 %
during an experiment. Data were filtered at 1 kHz, and
digitized at 10 kHz.
Cannulation surgery and microinjection
Mice were anesthetized with isoflurane (1–3 %, as
needed) inhalation with 30 % oxygen balanced with ni-
trogen. The scalp of mice were shaved and sterilized
with iodine and 75 % alcohol. The head of mice were
fixed onto a stereotaxic adapter mounted on a stereo-
taxic frame (Kopf model 962) and an incision was made
on the skull. Two holes of small diameter were drilled
on the dura to compensate for each lobes of the ACC
located at 0.7 mm anterior to bregma, 0.3 mm lateral
to the midline. The guide cannulas were placed into
the ACC (1.75 mm ventral to the surface of the skull).
After 10 days of recovery time, the mice were restrained
in a plastic cone (Braintree Scientific), and a 30 gauge
injection cannula was inserted 0.8 mm lower than the
guide. Microinjection was performed using a motorized
syringe pump (Razel Scientific Instruments) and a
Hamilton syringe. N,N,H,-trimethyl-5-[(tricyclo[3.3.1.13,7]-
dec-1-ylmethyl)amino]-1- pentanaminiumbromide hydro-
bromide (IEM 1460, Tocris Bioscience) was dissolved in
saline was delivered to left and right ACC (1 mM, 0.5 μl
per side in 10 min) through the cannula. After the delivery
to each side of the brain, the injection cannula was left
in place for 2 min to prevent any solution flowing out-
ward. The control mice were microinjected with 0.5 μl
saline per side of ACC. Behavioral tests were started at
45 min after injection.
Data analysis
The Data are presented as the mean ± SEM. Statistical
analyses of differences between the two groups were
tested by unpaired, two-tailed Student’s t-test. Compari-
son of multiple groups was performed with one-way
analysis of variance (ANOVA) (SPSS 19.0). Data were
analyzed by one-way ANOVA followed by post hoc com-
parison with least significant difference (LSD) test or
Dunnett’s T3 test according to homogeneity test. In all
cases, P < 0.05 was considered statistically significant.
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